103 related articles for article (PubMed ID: 26986816)
1. The Result of Multiple I-131 Treatments on the Effective Half-Life of Retained Radioactivity in Patients Ablated for Differentiated Thyroid Cancer: Possible Evidence for Thyroid Remnant Function Impairment.
Okkalides D
Cancer Biother Radiopharm; 2016 Mar; 31(2):58-64. PubMed ID: 26986816
[TBL] [Abstract][Full Text] [Related]
2. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
3. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer.
Welsh L; Powell C; Pratt B; Harrington K; Nutting C; Harmer C; Newbold K
J Clin Endocrinol Metab; 2013 May; 98(5):1819-25. PubMed ID: 23493434
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.
Samuel AM; Rajashekharrao B
J Nucl Med; 1994 Dec; 35(12):1944-50. PubMed ID: 7989975
[TBL] [Abstract][Full Text] [Related]
6. A dosimetric algorithm for patient-specific 131I therapy of thyroid cancer based on a prescribed target-mass reduction.
Traino AC; Di Martino F
Phys Med Biol; 2006 Dec; 51(24):6449-56. PubMed ID: 17148828
[TBL] [Abstract][Full Text] [Related]
7. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
8. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma.
Lin JD; Kao PF; Chao TC
Br J Radiol; 1998 Mar; 71(843):307-13. PubMed ID: 9616241
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
[TBL] [Abstract][Full Text] [Related]
10. Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario.
Campennì A; Giovanella L; Pignata SA; Violi MA; Siracusa M; Alibrandi A; Moleti M; Amato E; Ruggeri RM; Vermiglio F; Baldari S
Nucl Med Commun; 2015 Nov; 36(11):1100-6. PubMed ID: 26302462
[TBL] [Abstract][Full Text] [Related]
11. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma.
Long B; Li L; Yao L; Chen S; Yi H; Ye X; Xu D; Wu P
J Cancer Res Ther; 2015 Nov; 11 Suppl():C244-7. PubMed ID: 26612446
[TBL] [Abstract][Full Text] [Related]
12. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of 99mTc-pertechnetate single-photon emission computed tomography in remnant mass estimation of postsurgical patients of differentiated thyroid cancer during internal dosimetry.
Nadig MR; Pant GS; Bal C
Nucl Med Commun; 2008 Sep; 29(9):809-14. PubMed ID: 18677209
[TBL] [Abstract][Full Text] [Related]
14. Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements.
Pacilio M; Bianciardi L; Panichelli V; Argirò G; Cipriani C
Nucl Med Commun; 2005 Jul; 26(7):623-31. PubMed ID: 15942483
[TBL] [Abstract][Full Text] [Related]
15. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
Logue JP; Tsang RW; Brierley JD; Simpson WJ
Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
18. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
19. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
20. Thyroid Patient Salivary Radioiodine Transit and Dysfunction Assessment Using Chewing Gums.
Okkalides D
Cancer Biother Radiopharm; 2016 Nov; 31(9):330-341. PubMed ID: 27831763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
